Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes
- 9 March 2006
- journal article
- Published by Springer Nature in Investigational New Drugs
- Vol. 24 (5) , 393-401
- https://doi.org/10.1007/s10637-006-6335-5
Abstract
Purpose: The source of the pharmacokinetic variability of 9-nitrocamptothecin (9NC) and its 9-aminocamptothecin (9AC) metabolite is unknown. ATP-binding cassette (ABC) transporters have been reported to modulate camptothecin analogues, are associated with camptothecin resistance, and might also affect 9NC and 9AC pharmacokinetics. The aim of this study was to evaluate the functional consequence of known single nucleotide polymorphisms in the transporter genes ABCB1, ABCC2, and ABCG2 on the pharmacokinetic disposition of 9NC and 9AC. Experimental design: Pharmacokinetic and genotyping studies were performed in 55 patients as part of two phase I studies of 9NC in patients with refractory solid tumors, a phase II study of 9NC in patients with advanced colon cancer, and a study evaluating the disposition of 9NC after administration of a single dose under fasting conditions. DNA was isolated from plasma and analyzed for variants in ABCB1, ABCC2, and ABCG2 genes. The ABCB1 1236C>T (n = 43), ABCB1 2677G>T/A (n = 43), ABCB1 3435C>T (n = 43), ABCC2 3972C>T (n = 39), and ABCG2 421C>A (n = 42) variants were analyzed using Pyrosequencing. Results: The ABCG2 421C>A genotype significantly affected the pharmacokinetics of 9AC. The mean 9AC lactone AUC/dose for wild-type (n = 25) and heterozygous (n = 2) patients were 14.3 ng/mL · h and 51.1 ng/mL. h, respectively (P = 0.032). The mean ± SD 9AC total AUC/dose for wild-type (n = 39) and heterozygous (n = 3) patients were 91.9 ± 78.3 ng/mL · h and 129.0 ± 90.5 ng/mL · h, respectively (P = 0.40). 9NC and 9AC disposition were not significantly influenced by variants in ABCB1, ABCC2, and ABCG2, and ABCB1 and ABCC2, respectively (P>0.05). Conclusion: These findings suggest that inter-individual variability in 9AC disposition, but not 9NC, may be influenced, in part, by ABCG2 genotype. In contrast, there was no evidence for a relationship between ABCG2 and the disposition of 9NC, or for relationships between ABCB1 and ABCC2 genotypes and the disposition of 9NC or 9AC.Keywords
This publication has 44 references indexed in Scilit:
- Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping ProbesJNCI Journal of the National Cancer Institute, 2004
- ABCG2 PharmacogeneticsClinical Cancer Research, 2004
- Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumorsCancer Chemotherapy and Pharmacology, 2004
- Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecanPharmacogenetics, 2003
- Score Tests for Association between Traits and Haplotypes when Linkage Phase Is AmbiguousAmerican Journal of Human Genetics, 2002
- The Product of the ABC Half-Transporter Gene ABCG2 (BCRP/MXR/ABCP) Is Expressed in the Plasma MembraneBiochemical and Biophysical Research Communications, 2000
- Phase I Clinical and Pharmacological Studies of 20‐(S)‐Camptothecin and 20‐(S)‐9‐Nitrocamptothecin as Anticancer AgentsAnnals of the New York Academy of Sciences, 1996
- Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags databaseHuman Molecular Genetics, 1996
- Evolution of ATP-binding cassette transporter genesCurrent Opinion in Genetics & Development, 1995
- The role of pH and serum albumin in the metabolic conversion of 9-nitrocamptothecin to 9-aminocamptothecin by human hematopoietic and other cellsEuropean Journal of Haematology, 1995